{"id":"W4416387684","doi":"10.1016/j.annonc.2025.09.054","title":"LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Institute of Cancer Research; Seoul St. Mary's Hospital, Catholic University of Korea; Instituto de Salud Carlos III; Amgen; lékařská fakulta Univerzity Karlovy; Yonsei University College of Medicine; Taipei Veterans General Hospital; Saitama Medical University; Catholic University of Korea; Yonsei University; Univerzita Karlova v Praze; Mersana Therapeutics; AstraZeneca; Merck; Daiichi-Sankyo","keywords":"Ovarian cancer; Phases of clinical research; Primary (astronomy); Cancer; Ovary","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640063,0.0009203372,0.001651299,0.000496079,0.0002150021,0.0009443356,0.0006340744,0.0006354958,0.002426906],"category_scores_gemma":[0.001116036,0.0004531488,0.001586693,0.0006519672,0.0005323934,0.0006115134,0.0004233739,0.002332081,0.0004711391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009588508,"about_ca_system_score_gemma":0.001332526,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001589966,"about_ca_topic_score_gemma":0.00653091,"domain_scores_codex":[0.9993666,0.0003740816,0.00002804154,0.00009391151,0.00004942497,0.00008803461],"domain_scores_gemma":[0.9994049,0.0001349478,0.000159328,0.00005892806,0.00002656917,0.0002153721],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.677741,0.02065772,0.03907654,0.001095493,0.00389253,0.0001407609,0.0002201042,0.006141007,0.02069077,0.0003658085,0.005774852,0.2242034],"study_design_scores_gemma":[0.4292745,0.4016198,0.1440201,0.0001437459,0.003073298,0.0006448565,0.0001796233,0.004172146,0.005825863,0.0004536858,0.01051461,0.00007776159],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910981,0.003551271,0.0003275298,0.000512288,0.00005262908,0.0007691846,0.002063973,0.00007978077,0.00154531],"genre_scores_gemma":[0.9876289,0.002984413,0.001265646,0.0006616038,0.00009392589,0.0007052764,0.004422289,0.000033775,0.002204087],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002426906,"threshold_uncertainty_score":0.008673608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04016149790392913,"score_gpt":0.3770746092146255,"score_spread":0.3369131113106964,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}